Product Description
IGN002 is a novel recombinant protein comprised of anti-CD20 antibody (rituximab) fused to human IFN_2b by a peptide linker.
Mechanisms of Action: CD20 Antagonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IGN002-201 | P1 |
Withdrawn |
Lymphoma, Non-Hodgkin |
2025-07-01 |
50% |
| NHL | P1 |
Terminated |
Lymphoma, Non-Hodgkin |
2018-05-04 |
50% |